Sepsis Clinical Trial
— FORTRESSOfficial title:
An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients With Fosfomycin i.v.
NCT number | NCT02979951 |
Other study ID # | FORTRESS |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | December 2016 |
Est. completion date | December 2030 |
The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | December 2030 |
Est. primary completion date | December 2030 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female patients aged = 18 years - Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v. - Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis/central nervous system infection, bacteraemia/sepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC - Written informed consent of the participant (or person in charge in case of patients incapable of giving consent) Exclusion Criteria: - Previous documentation of the patient in the present study - Patients participating in an interventional clinical trial - Patients with known hypersensitivity to fosfomycin or any of the excipients - Terminally ill patients - Patients with "do not resuscitate order" - Palliative treatment approach - Failure of > 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney - Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS) - Fosfomycin treatment as 4th line treatment or at later stage - Patients with involvement of fungi or mycobacteria in the targeted infection |
Country | Name | City | State |
---|---|---|---|
Austria | Landeskrankenhaus Hall - Tirol Kliniken | Hall In Tirol | |
Austria | A.ö. Bezirkskrankenhaus | Reutte | |
Austria | Klinikum Wels-Grieskirchen, Institut für Hygiene und Mikrobiologie | Wels | |
Austria | AKH Wien, Universitätsklinik für Innere Medizin 1 | Wien | |
Germany | Universitätsmedizin Charité | Berlin | |
Germany | Vivantes Kliniken Neukölln | Berlin | |
Germany | Städtisches Klinikum Braunschweig | Braunschweig | |
Germany | Universitäts Düsseldorf; Klinik für Anästhesiologie | Dusseldorf | |
Germany | Universitätsklinikum Frankfurt | Frankfurt | |
Germany | Universität Hamburg-Eppendorf | Hamburg | |
Germany | Universitätsklinikum Jena; Zentrum für Infektionsmedizin | Jena | |
Germany | Universitätsklinikum Schleswig-Holstein | Kiel | |
Germany | Universitätsklinik Schleswig-Holstein | Lübeck | |
Germany | LMU München | München | |
Germany | Universitätsklinikum Münster | Münster | |
Germany | Klinikum Oldenburg | Oldenburg in Holstein | |
Germany | Universitätsklinik Regensburg; Klinik für Anästhesiologie | Regensburg | |
Germany | Kliniken Nordoberpfalz | Weiden | |
Greece | RIO Univ. Hospital, Dept of Pathology, Division of Infectious Diseases | Patras | |
Italy | Clinical Malattie Infettive | Bari | |
Italy | Azienda Ospedaliera S.Croce e Carle | Cuneo | |
Italy | Ospedal Policlinico San Martino | Genova | |
Italy | Ospedale L. Sacco | Mailand | |
Italy | Istituto Mediterraneo per i Trapianti Ismett IRCCS | Palermo | |
Italy | Policlinico Paolo Giaccone | Palermo | |
Italy | Lazzaro Spallanzani | Rom | |
Italy | Policlinico Umberto I, Malattie Infettive | Rom | |
Italy | Polocinico Tor Vergata | Rom | |
Italy | AOU Città della Salute e Scienza-Presidio Molinette | Torino | |
Italy | Ospedale S.M.della Misericordia | Udine | |
Italy | ASST-Sette Lagh Viale Borre | Varese | |
United Kingdom | Royal Bolton Hospital | Bolton | |
United Kingdom | Hull & East Yorkshire Hospitals NHS Trust | Cottingham | |
United Kingdom | Ninewells Hospital | Dundee | |
United Kingdom | Queen Elisabeth University Hospital | Glasgow | |
United Kingdom | University of Glasgow/Royal Infirmary | Glasgow | |
United Kingdom | University Hospital Crosshouse | Kilmarnock | |
United Kingdom | Chelsea & Westminster Hospial | London | |
United Kingdom | Queen Elisabeth Hospital | London | |
United Kingdom | Univresity College Londen (UCL) Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Infectopharm Arzneimittel GmbH | Dr. Oestreich + Partner GmbH, INPADS GmbH |
Austria, Germany, Greece, Italy, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients with clinical success as defined as clinical cure or clinical improvement | Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of clinical improvement (both criteria must be fulfilled): Partial resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "End of fosfomycin treatment" (EOT) is reached at the day of the last fosfomycin application in the course of the treatment schedule for the targeted infection (i.e., in case of a multiple stage treatment schedule, the end of the last fosfomycin treatment phase). |
Analysed at EOT ("End of fosfomycin treatment", up to 6 months after start of fosfomycin treatment) | |
Secondary | Microbiological cure | Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "initial response" is defined to be after start of fosfomycin treatment and not later than 7 days after start of fosfomycin treatment. |
Analysed at "initial response" (not later than 7 days after start of fosfomycin treatment) | |
Secondary | Microbiological cure | Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "End of fosfomycin treatment" (EOT) is reached at the day of the last fosfomycin application in the course of the treatment schedule for the targeted infection (i.e., in case of a multiple stage treatment schedule, the end of the last fosfomycin treatment phase). |
Analysed at EOT ("End of fosfomycin treatment", up to 6 months after start of fosfomycin treatment) | |
Secondary | Microbiological cure | Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "TOC" is defined to be not earlier than EOT and not later than end of hospital stay of the patient. |
Analysed at TOC ("Test of cure", up to 6 months after start of fosfomycin treatment) | |
Secondary | Microbiological cure | Definition of microbiological cure:
Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Defined to be after end of hospital stay + within 1 year after start of fosfomycin treatment. Either the latest visit after "End of hospital stay" within 1 year after start of fosfomycin treatment or, if applicable, the visit in this time frame assessing a clinical failure/relapse. |
Analysed at follow-up (within one year after start of fosfomycin treatment) (only for indication "osteomyelitis") | |
Secondary | Clinical success as defined as clinical cure or clinical improvement | Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of clinical improvement (both criteria must be fulfilled): Partial resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "initial response" is defined to be after start of fosfomycin treatment and not later than 7 days after start of fosfomycin treatment. |
Analysed at "initial response" (not later than 7 days after start of fosfomycin treatment) | |
Secondary | Clinical success as defined as clinical cure or clinical improvement | Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of clinical improvement (both criteria must be fulfilled): Partial resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "TOC" is defined to be not earlier than EOT and not later than end of hospital stay of the patient. |
Analysed at TOC ("Test of cure", up to 6 months after start of fosfomycin treatment) | |
Secondary | Clinical success as defined as clinical cure or clinical improvement | Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of clinical improvement (both criteria must be fulfilled): Partial resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Defined to be after end of hospital stay + within 1 year after start of fosfomycin treatment. Either the latest visit after "End of hospital stay" within 1 year after start of fosfomycin treatment or, if applicable, the visit in this time frame assessing a clinical failure/relapse. |
Analysed at follow-up (within one year after start of fosfomycin treatment) (only for indication "osteomyelitis") | |
Secondary | Clinical cure | Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "End of fosfomycin treatment" (EOT) is reached at the day of the last fosfomycin application in the course of the treatment schedule for the targeted infection (i.e., in case of a multiple stage treatment schedule, the end of the last fosfomycin treatment phase). |
Analysed at EOT ("End of fosfomycin treatment", up to 6 months after start of fosfomycin treatment) | |
Secondary | Clinical cure | Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "TOC" is defined to be not earlier than EOT and not later than end of hospital stay of the patient. |
Analysed at TOC ("Test of cure", up to 6 months after start of fosfomycin treatment) | |
Secondary | Clinical cure | Definition of clinical cure (both criteria must be fulfilled):
Resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Defined to be after end of hospital stay + within 1 year after start of fosfomycin treatment. Either the latest visit after "End of hospital stay" within 1 year after start of fosfomycin treatment or, if applicable, the visit in this time frame assessing a clinical failure/relapse. |
Analysed at follow-up (within one year after start of fosfomycin treatment) (only for indication "osteomyelitis") | |
Secondary | Clinical improvement | Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "initial response" is defined to be after start of fosfomycin treatment and not later than 7 days after start of fosfomycin treatment. |
Analysed at "initial response" (not later than 7 days after start of fosfomycin treatment) | |
Secondary | Clinical improvement | Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "End of fosfomycin treatment" (EOT) is reached at the day of the last fosfomycin application in the course of the treatment schedule for the targeted infection (i.e., in case of a multiple stage treatment schedule, the end of the last fosfomycin treatment phase). |
Analysed at EOT ("End of fosfomycin treatment", up to 6 months after start of fosfomycin treatment) | |
Secondary | Clinical improvement | Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Time point "TOC" is defined to be not earlier than EOT and not later than end of hospital stay of the patient. |
Analysed at TOC ("Test of cure", up to 6 months after start of fosfomycin treatment) | |
Secondary | Clinical improvement | Definition of clinical improvement (both criteria must be fulfilled):
Partial resolution of signs and symptoms and microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Definition of microbiological cure: Elimination of the relevant pathogen(s) at the relevant site(s) of infection (at least one negative culture) or in case "no sample available/indicated due to sufficient clinical response", pathogen elimination is considered. Time Frame: Defined to be after end of hospital stay + within 1 year after start of fosfomycin treatment. Either the latest visit after "End of hospital stay" within 1 year after start of fosfomycin treatment or, if applicable, the visit in this time frame assessing a clinical failure/relapse. |
Analysed at follow-up (within one year after start of fosfomycin treatment) (only for indication "osteomyelitis") | |
Secondary | Sodium serum levels | On every day from start of fosfomycin treatment until end of hospital stay (up to 6 months after start of fosfomycin treatment) | ||
Secondary | Potassium serum levels | On every day from start of fosfomycin treatment until end of hospital stay (up to 6 months after start of fosfomycin treatment) | ||
Secondary | Adverse events | On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment) | ||
Secondary | Non-serious adverse events | On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment) | ||
Secondary | Serious adverse events | On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment) | ||
Secondary | Cases of death | On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment) | ||
Secondary | Adverse drug reactions (ADRs) | On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment) | ||
Secondary | Serious adverse drug reactions (SADRs) | On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment) | ||
Secondary | Dropouts due to treatment failure or due to adverse events | On every day from start of fosfomycin treatment until end of follow-up (up to one year after start of fosfomycin treatment) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |